How one of the EU's largest regulators is adapting to new technological demands
This article was originally published in Clinica
The surge in development of innovative products in human tissue engineering, nanotechnology and other product areas on the drug/device borderline is placing increasingly tough demands on national regulators. Amanda Maxwell interviewed Professor Kent Woods, the chief executive of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), to see how one of the EU's largest competent authorities is managing
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.